abrdn Life Sciences Investors (NYSE:HQL) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

abrdn Life Sciences Investors (NYSE:HQL) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $18.27 and traded as high as $18.70. abrdn Life Sciences Investors shares last traded at $18.6340, with a volume of 136,356 shares trading hands.

abrdn Life Sciences Investors Trading Up 1.4%

The firm’s 50-day moving average price is $18.58 and its 200 day moving average price is $18.28.

abrdn Life Sciences Investors Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, January 12th. Shareholders of record on Friday, November 20th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 31.7%. The ex-dividend date of this dividend is Friday, November 20th.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Several large investors have recently made changes to their positions in the company. Flagship Harbor Advisors LLC boosted its position in shares of abrdn Life Sciences Investors by 4.1% during the third quarter. Flagship Harbor Advisors LLC now owns 417,366 shares of the company’s stock worth $7,805,000 after buying an additional 16,601 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in abrdn Life Sciences Investors by 57.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company’s stock worth $5,898,000 after buying an additional 132,098 shares in the last quarter. Advisors Asset Management Inc. acquired a new stake in abrdn Life Sciences Investors in the 3rd quarter valued at approximately $3,907,000. Formidable Asset Management LLC increased its position in abrdn Life Sciences Investors by 0.7% in the 3rd quarter. Formidable Asset Management LLC now owns 166,324 shares of the company’s stock valued at $3,328,000 after acquiring an additional 1,081 shares during the period. Finally, 180 Wealth Advisors LLC increased its position in abrdn Life Sciences Investors by 2.2% in the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after acquiring an additional 3,271 shares during the period. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors is a non-diversified, closed-end investment fund focused on companies in the life sciences and health care sectors. Rather than developing or selling products itself, the fund invests in businesses involved in areas such as biotechnology, pharmaceuticals, medical devices and related services. The fund seeks long-term capital appreciation through a portfolio that can include both publicly traded and privately held companies. Its investments may span U.S. and international markets.